PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

De Bruycker, A; Spiessens, A; Dirix, P; Koutsouvelis, N; Semac, I; Liefhooghe, N; Gomez-Iturriaga, A; Everaerts, W; Otte, F; Papachristofilou, A; Scorsetti, M; Shelan, M.; Siva, S; Ameye, F; Guckenberger, M; Heikkilä, R; Putora, P. M.; Zapatero, A; Conde-Moreno, A; Couñago, F; ... (2020). PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC cancer, 20(1), p. 406. BioMed Central 10.1186/s12885-020-06911-4

document.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (665kB) | Preview


Pelvic nodal recurrences are being increasingly diagnosed with the introduction of new molecular imaging techniques, like choline and PSMA PET-CT, in the restaging of recurrent prostate cancer (PCa). At this moment, there are no specific treatment recommendations for patients with limited nodal recurrences and different locoregional treatment approaches are currently being used, mostly by means of metastasis-directed therapies (MDT): salvage lymph node dissection (sLND) or stereotactic body radiotherapy (SBRT). Since the majority of patients treated with MDT relapse within 2 years in adjacent lymph node regions, with an estimated median time to progression of 12-18 months, combining MDT with whole pelvic radiotherapy (WPRT) may improve oncological outcomes in these patients. The aim of this prospective multicentre randomized controlled phase II trial is to assess the impact of the addition of WPRT to MDT and short-term androgen deprivation therapy (ADT) on metastasis-free survival (MFS) in the setting of oligorecurrent pelvic nodal recurrence.


Patients diagnosed with PET-detected pelvic nodal oligorecurrence (≤5 nodes) following radical local treatment for PCa, will be randomized in a 1:1 ratio between arm A: MDT and 6 months of ADT, or arm B: WPRT added to MDT and 6 months of ADT. Patients will be stratified by type of PET-tracer (choline, FACBC or PSMA) and by type of MDT (sLND or SBRT). The primary endpoint is MFS and the secondary endpoints include clinical and biochemical progression-free survival (PFS), prostate cancer specific survival, quality of life (QoL), toxicity and time to castration-resistant prostate cancer (CRPC) and to palliative ADT. Estimated study completion: December 31, 2023.


This is the first prospective multicentre randomized phase II trial assessing the potential of combined WPRT and MDT as compared to MDT alone on MFS for patients with nodal oligorecurrent PCa.

TRIAL REGISTRATION Identifier: NCT03569241, registered June 14, 2018, ; Identifier on Swiss National Clinical Trials Portal (SNCTP): SNCTP000002947, registered June 14, 2018.

Item Type:

Journal Article (Further Contribution)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Shelan, Mohamed and Putora, Paul Martin


600 Technology > 610 Medicine & health




BioMed Central




Beatrice Scheidegger

Date Deposited:

28 May 2020 11:49

Last Modified:

31 May 2020 02:45

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Androgen deprivation therapy Metastasis-directed therapy Oligometastases Oligorecurrence Prostate cancer Quality of life Salvage lymph node dissection Stereotactic body radiotherapy Survival Whole pelvic radiotherapy




Actions (login required)

Edit item Edit item
Provide Feedback